Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Increased by Atomi Financial Group Inc.

Atomi Financial Group Inc. boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 13.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,179 shares of the pharmaceutical company’s stock after buying an additional 262 shares during the quarter. Atomi Financial Group Inc.’s holdings in Vertex Pharmaceuticals were worth $877,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of VRTX. Transform Wealth LLC raised its position in shares of Vertex Pharmaceuticals by 3.7% during the fourth quarter. Transform Wealth LLC now owns 24,900 shares of the pharmaceutical company’s stock worth $10,027,000 after purchasing an additional 891 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Vertex Pharmaceuticals by 5.8% during the 4th quarter. Crossmark Global Holdings Inc. now owns 6,207 shares of the pharmaceutical company’s stock worth $2,499,000 after buying an additional 341 shares during the period. Sugar Maple Asset Management LLC purchased a new stake in Vertex Pharmaceuticals during the fourth quarter valued at about $35,000. Ballentine Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals by 2.2% in the fourth quarter. Ballentine Partners LLC now owns 5,590 shares of the pharmaceutical company’s stock worth $2,251,000 after buying an additional 119 shares during the period. Finally, Atwood & Palmer Inc. increased its position in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. Atwood & Palmer Inc. now owns 55,390 shares of the pharmaceutical company’s stock worth $22,306,000 after acquiring an additional 1,130 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $428.00 on Thursday. The stock has a 50-day simple moving average of $438.10 and a 200 day simple moving average of $465.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The stock has a market capitalization of $110.22 billion, a PE ratio of -215.08, a P/E/G ratio of 2.17 and a beta of 0.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.67 earnings per share. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research analyst reports. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. BMO Capital Markets dropped their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. Citigroup initiated coverage on Vertex Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $575.00 price objective for the company. Finally, UBS Group upped their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.